VALBIOTIS announced Phase I/II positive results on VAL-070 in hypercholesterolemia, which validate safety, tolerance and blood LDL-cholesterol as the primary endpoint of the Phase II clinical studies.
Cécile Merle appointed to the position of Quality Assurance DirectorJune 19th 2018
VALBIOTIS announces the appointment of Cécile Merle to the position of Quality Assurance Director
VALBIOTIS confirms its deployment in the United-States, to prepare the future commercialization of VALEDIAJune 7th 2018
VALBIOTIS announces its integration into the French Tech in Boston, Massachusetts, and the development of investors relations in the USA.
The clinical development of VALEDIA® initiated in the USAMay 15th 2018
VALBIOTIS announces the authorization received to launch the international REVERSE-IT study in the United States as well as first discussions with the FDA.